The instant invention provides a process for reducing the drying time of softgel capsules by incorporating drying accelerators based on organic sulfonic acids and salts thereof into the formulations used to make the capsules.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

The present disclosure relates to the field of oral mucoadhesive dosage forms and the type and amounts of structural components to improve mucoadhesion. The present disclosure further relates to combinations of active ingredients within a mucoadhesive dosage form.

The present disclosure relates to the field of oral mucoadhesive dosage forms and the type and amounts of structural components to improve mucoadhesion. The present disclosure further relates to combinations of active ingredients within a mucoadhesive dosage form.

Disclosed are pharmaceutical compositions having a portion of ketamine for intraoral release and another ketamine for gastrointestinal release. The compositions can further include aspirin. The disclosed formulations and related administration approaches improve the bioavailability and efficacy of oral ketamine.

Disclosed are pharmaceutical compositions having a portion of ketamine for intraoral release and another ketamine for gastrointestinal release. The compositions can further include aspirin. The disclosed formulations and related administration approaches improve the bioavailability and efficacy of oral ketamine.

A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.

A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.

A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.